ANAB (60) GHRS (49) TYRA (31) AAPG (47) ⌘ Pro Terminal →

Pacira BioSciences Inc. (PCRX) — RQD Stock Rating Cockpit

$36.39 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $36.32

Pacira BioSciences Inc. (PCRX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.45B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $36.39 (0.00% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, PCRX ranks #126 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PCRX compare to ANAB and GHRS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, ANAB (AnaptysBio Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC 85.0%, cap $1.44B) and GHRS (GH Research PLC) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.47B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCRX?

▼

Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $36.32 (-0.19%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 18.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCRX)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY PCRX SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 2.33 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 2.6% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$36.35+0% Next Q

Q2 (-2Q)

Grade C$36.34+0.1% Next Q

Q3 (-1Q)

Grade C+$36.38+0% Next Q

Current

Grade C$36.39+1.3% Hist 90D α

Trajectory: C (57) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PCRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, PCRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 76.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.30) or 200D SMA ($24.92) invalidates the momentum regime and cuts Target Base ($37.54) toward Bear Floor ($29.28).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PCRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERBOUGHT (>70)

83.230 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.33>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE98% OF RANGE

L: $19$36.39H: $37

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on PCRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

1.7% ROIC with 79.4% gross margin and 9.42% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.33 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (72)

29/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like PCRX

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PCRX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PCRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.39%▲ ASCENDING CHANNEL

2026-11-02O $36.39H $36.39L $36.39C $36.39VOL 619.0K

RES: $38.08SUP: $25.49SMA50: $29.30SMA200: $24.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCRX Butterfly Map → + Track PCRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

43.5%/yr Implied 5Y Growth

vs. +3.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PCRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PCRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCRX)

Health Care Rank #126 of 1016 ⚔️ ANAB vs PCRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCRX vs. ANAB, GHRS, TYRA, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pacira BioSciences Inc. (PCRX) ranks #126 by composite RQD confidence (65/100, grade C) and #308 by equity capitalization ($1.45B). Within this direct 5-issuer industry benchmark cohort, PCRX leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PCRX currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PCRX ACTIVE Pacira BioSciences Inc.	C	65/100	—	79.4%	1.7%	0.00%	$1.45B	Benchmark Subject
ANAB AnaptysBio Inc.	C-	60/100	—	—	85.0%	-3.68%	$1.44B	/anab-vs-pcrx →
GHRS GH Research PLC	D	49/100	—	—	—	+3.82%	$1.47B	/ghrs-vs-pcrx →
TYRA Tyra Biosciences Inc.	E	31/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-pcrx →
AAPG Ascentage Pharma Group International American Depository Shares	D	47/100	—	—	—	-0.70%	$1.39B	/aapg-vs-pcrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001396814

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported GAAP revenue of $726.4M (+3.6% vs. FY2024 revenue of $701.0M , and +7.6% cumulative change since FY2023) , GAAP net income of $7.0M, operating cash flow of $152.0M, and free cash flow of $136.7M (-23.5% YoY). On the balance sheet, PCRX closed FY2025 with $1.26B in total assets against $372.2M in total debt (Altman Z-Score: 2.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$726.4M	$7.0M	$152.0M	$136.7M	$1.26B	$372.2M
FY2024 (FY)	2024-12-31	$701.0M	-$99.6M	$189.4M	$178.8M	$1.55B	$383.5M
FY2023 (FY)	2023-12-31	$675.0M	$42.0M	$154.6M	$154.6M	—	—

3. PCRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PCRX compare to ANAB and GHRS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PCRX?

Where is PCRX trading relative to its 50-day, 200-day, and 52-week technical levels?

PCRX last traded at $36.39 (0.00% on volume of 618,971 shares), positioning the stock +24.20% above its 50-day simple moving average ($29.30) and +46.03% above its 200-day simple moving average ($24.92). Across its 52-week range of $18.80 to $36.67, PCRX sits at the 98.4% percentile with a 14-day RSI of 83.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±1.8% ($35.73 to $37.05).

PCRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PCRX stock right now?

Pacira BioSciences Inc. (PCRX) currently earns a Roarable Rating of C (Hold — HOLD) with 65/100 RQD Confidence. Solid 79% profit margin (2% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

What is PCRX's 12-month price target and RQD AI Jury consensus?

PCRX's 12-month base price target is $37.54 (range $29.28 to $44.3), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PCRX RQD Cockpit PCRX 12M Forecast PCRX Earnings & Move PCRX Dividends & DRIP PCRX Insiders & 13F PCRX Whale Options PCRX Profit Sankey PCRX News & Why